Third Harmonic Bio, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Third Harmonic Bio, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2021 to Q2 2024.
  • Third Harmonic Bio, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $2.61M, a 8.33% decline year-over-year.
  • Third Harmonic Bio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $8.88M, a 2.45% increase year-over-year.
  • Third Harmonic Bio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $9.58M, a 102% increase from 2022.
  • Third Harmonic Bio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4.75M, a 832% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $8.88M $2.61M -$237K -8.33% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $9.12M $2.22M -$459K -17.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $9.58M $1.76M -$377K -17.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-26
Q3 2023 $9.95M $2.29M +$1.29M +128% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $8.67M $2.85M +$1.69M +145% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $6.98M $2.68M +$2.23M +496% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $4.75M $2.14M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 $1.01M +$869K +634% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $1.16M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $450K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q3 2021 $137K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.